Chargement en cours...
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2676549/ https://ncbi.nlm.nih.gov/pubmed/19367282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605016 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|